CDKN2A and osteosarcoma: Moreover, they highlighted a discrepancy between CDKN2A homozygous deletions in osteosarcoma and EWS cell lines (42 and 36%, respectively) compared to primary sarcoma samples, in which the frequency of this deletion is expected to be lower.